Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Table 1 Baseline demographic and disease characteristics

Demographic characteristic	OASIS		Adalimumab		Pvalue^a
	Number	Baseline assessment	Number	Baseline assessment
Age, years	168	43.6 ± 12.7	307	41.8 ± 11.5	0.101
Male, percentage	169	69.2	307	76.5	0.102
Weight, kg	157	72.7 ± 12.8	307	80.0 ± 16.3	< 0.001
Height, cm	161	171.0 ± 9.3	306	172.9 ± 9.5	0.037
Concomitant medications, percentage
NSAIDs	169	77.5	307	88.3
DMARDs	169	9.5	307	21.8
Systemic glucocorticoids	169	1.8	307	9.8
Disease characteristic
Disease duration, years	163	11.3 ± 8.7	307	11.2 ± 9.3	0.946
BASDAI, 0-10	166	3.4 ± 2.1	307	6.2 ± 1.7	< 0.001
BASFI, 0-10	158	3.1 ± 2.4	307	5.3 ± 2.1	< 0.001
Total back pain, 0-10	166	3.5 ± 2.4	307	6.7 ± 1.9	< 0.001
Inflammation, 0-10^b	167	3.4 ± 2.6	307	6.7 ± 2.0	< 0.001
Patient's Global Assessment of disease activity, 0-10	165	3.7 ± 2.7	306	6.4 ± 2.0	< 0.001
C-reactive protein, mg/dL^c	160	1.5 ± 1.9	302	1.9 ± 2.5	0.036
mSASSS, 0-72	169	15.8 ± 17.6	307	19.8 ± 19.3	0.028

Values are mean ± standard deviation unless otherwise noted. ^aP values calculated using one-way analysis of variance or the Fisher exact test. No statistical comparison of concomitant medications was completed. ^bMean of questions 5 and 6 of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ^cUsing the ultrasensitive assay (normal range, 0.007 to 0.494 mg/dL). BASFI, Bath Ankylosing Spondylitis Functional Index; DMARD, disease-modifying antirheumatic drug; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAID, nonsteroidal anti-inflammatory drug; OASIS, Outcome in Ankylosing Spondylitis International Study.

ISSN: 1478-6362